AP-24534 |
ICLUSIG |
PONATINIB |
ICLUSIG® |
PONATINIBUM |
AP24534 |
AP 24534 |
chembl:CHEMBL1171837 |
drugbank:08901 |
rxcui:1364347 |
pubchem.compound:24826799 |
chemidplus:943319-70-8 |
FDA Approval | Chronic myelogenous leukemia, Acute lymphoblastic leukemia (Philadelphia chromosome positive) |
Drug Class | Kinase Inhibitors |
Drug Categories | cytochrome p-450 cyp2c8 substrates |
Drug Class | small molecule |
Drug Indications | antineoplastic agent |
FDA Approval | not approved |
Drug Groups | investigational |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | hepatotoxic agents |
Drug Categories | immunosuppressive agents |
Drug Categories | kinase inhibitor |
Drug Categories | narrow therapeutic index drugs |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | tyrosine kinase inhibitors |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Inhibition of recombinant RIPK3 in an <i>in vitro</i> ADP-Glo assay (Promega). |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Drug family | BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor |
Alteration | ABL1:T315I |
Alteration | ABL1__BCR |
inhibitor (inhibitory) |
Drug family | BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor |
Alteration | FLT3:D835.,Y842. |
Indication/Tumor Type | acute myeloid leukemia |
inhibitor (inhibitory) |
Alteration | FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E |
Drug family | BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor |
Clinical Status | preclinical |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Inhibition of recombinant RIPK1 in an <i>in vitro</i> ADP-Glo assay (Promega). |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Inhibition of recombinant RIPK2 in an <i>in vitro</i> ADP-Glo assay (Promega). |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Drug family | BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor |
Alteration | KIT:788-828,829-860,550-592 |
Alteration | KIT:A829P,V654A,T670I |
inhibitor (inhibitory) |
Details of the Assay for Interaction | CDK19/cyclin C. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Evidence Type | Actionable |
Approval Status | Preclinical - Pdx |
Response Type | no benefit |
inhibitor (inhibitory) |
Details of the Assay for Interaction | CDK8/cyclin C. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
PONATINIB | DrugBank Drug Name |
943319-70-8 | CAS Number |
Iclusig | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
AP24534 | Development Name |
PONATINIB | Generic Name |
ICLUSIG | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Chronic myelogenous leukemia, Acute lymphoblastic leukemia (Philadelphia chromosome positive) |
FDA Approval | not approved |
Drug Indications | antineoplastic agent |
Drug Class | small molecule |
CHEMBL1171837 | ChEMBL Drug ID |
PONATINIB | Primary Drug Name |
PONATINIB | Drug Generic Name |
AP24534 | Drug Synonym |
D0H0EQ | TTD Drug ID |
PONATINIB | GuideToPharmacology Ligand Name |